Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in advanced renal cell carcinoma
NCT00827359Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Mar 2009
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in renal cell carcinoma (RCC), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Difference in Median Progression Free Survival Time Between Favorable and Unfavorable Biomarker Group at 39 months. Started Mar 2009; status: completed.
02
Drugs
everolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00827359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00827359.